The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing if combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials.
http://ift.tt/2fqnkE8
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου